Crescita Therapeutics

Crescita Skin Science is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. It offers a portfolio of high-quality, science-based non-prescription skincare products and early-to-commercial-stage prescription products. The company also owns multiple proprietary transdermal delivery platforms that support the development of patented formulations for delivering active ingredients into or through the skin.

Crescita Skin Science is a Canadian commercial dermatology company with a portfolio of prescription and non-prescription products for the treatment and care of skin conditions. It is growth-oriented and innovation-driven, with in-house R&D and manufacturing capabilities. The company offers non-prescription skincare products and early-to-commercial-stage prescription products, and owns multiple proprietary transdermal delivery platforms.

• 2020-11-05

  Crescita licenses Pliaglis commercialization and development in mainland China[4]Crescita 授权在中国大陆商业化和开发 Pliaglisprnewswire.com

  Reported: 2020-11-05

  Crescita Therapeutics announced an exclusive agreement with Juyou-Biotechnology for the commercialization and development of Pliaglis in mainland China. Juyou will handle clinical development and regulatory filings; the product could launch as early as 2023 if no additional studies are required.

• 2020-01-22

  Crescita announces a $3.5 million credit facility with RBC[5]Crescita宣布与RBC设立350万美元信贷额度newswire.ca

  Reported: 2020-01-22

  Crescita Therapeutics announced that it had secured a $3.5 million revolving demand operating credit facility with the Royal Bank of Canada. The facility's closing remained subject to steps required to grant RBC security over Crescita's receivables and inventories.

• 2020-01-22

  Crescita announces a $3.5 million credit facility[6]Crescita宣布350万美元信贷额度prnewswire.com

  Reported: 2020-01-22

  Crescita Therapeutics announced a $3.5 million revolving demand operating credit facility with the Royal Bank of Canada after repaying its Knight Therapeutics loan. The facility's closing remained subject to granting RBC a first-ranking charge over Crescita's receivables and inventories.

• 2020-01-20

  Crescita enters exclusive distribution agreement with FILLMED[7]Crescita与FILLMED签订独家分销协议prnewswire.com

  Reported: 2020-01-20

  Crescita Therapeutics announced that it had entered into an agreement with FILLMED for exclusive distribution in Canada of the ART-FILLER injectables range and NCTF products.

1. 1Canadian Dermatology Company | Crescita Skin Sciencecrescitatherapeutics.com
2. 2Products | Crescita Skin Sciencecrescitatherapeutics.com
3. 3About Us | Crescita Skin Sciencecrescitatherapeutics.com
4. 4Crescita 授权在中国大陆商业化和开发 Pliaglisprnewswire.com
5. 5Crescita宣布与RBC设立350万美元信贷额度newswire.ca
6. 6Crescita宣布350万美元信贷额度prnewswire.com
7. 7Crescita与FILLMED签订独家分销协议prnewswire.com
8. 8Crescita Signs Exclusive Distribution Agreement with FILLMEDnewswire.ca